Introduction#
Sana Biotechnology, Inc. has announced that an abstract detailing its research on a new CAR T therapy, SG293, has been accepted for oral presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. This event is a significant platform for sharing advancements in gene and cell therapy.
Presentation Details#
The presentation is scheduled for May 12, 2026, from 8:15 to 8:30 a.m. ET at the MCEC Room 257AB in Boston. The abstract, titled "Potent, safe, and cell-specific in vivo generation of CAR-T cells in NHPs with SG293," will be featured in a session focused on innovative gene delivery methods that do not rely on adeno-associated viral (AAV) vectors.
About SG293#
SG293 is designed to target CD19, a protein often found on the surface of certain cancerous B cells. This therapy employs a unique delivery technology that aims to introduce genetic material specifically into CD8+ T cells, which are crucial for the immune response. By doing so, it seeks to create CAR T cells that can effectively target and eliminate B-cell cancers while minimizing effects on other tissues, like the liver.
Future Directions#
Sana Biotechnology plans to investigate SG293 for treating both B-cell cancers and autoimmune diseases related to B-cells. The company is committed to developing engineered cell therapies to improve patient outcomes. Additionally, Sana has recently partnered with the Mayo Clinic to enhance its investigational therapy for type 1 diabetes, showcasing its commitment to advancing medical treatments.
These developments underscore Sana Biotechnology's ongoing efforts to innovate in the field of gene and cell therapy, aiming to bring new solutions to patients in need.